pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

Alentis Therapeutics AG

updated 3mo ago
Website ↗
community read0 votes

🐶 often sniffed alongside

top 5
  • tagImmunology1 co-mentions · 1 sources
  • tagNephrology1 co-mentions · 1 sources
  • tagMonoclonal Antibody1 co-mentions · 1 sources
  • drugImmunology1 co-mentions · 1 sources
  • druglixudebart1 co-mentions · 1 sources
pipeline
2
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0

Pipeline(2)

pipeline depth2 products
Phase 2: 1Unknown: 1
1Phase 21Unknown
Phase 2
ALEP-02
Cervical Cancer
drug
lixudebart

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase2A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumorsrecruitingn=235
  • phase2Rescue of Nephrons With ALE.F02 (RENAL-F02)recruitingn=80
  • phase2A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumorsrecruitingn=180
  • phase2Study of ALE.C04 in Patients With Head and Neck Cancerterminatedn=21
  • phase1A Clinical Trial of ALE.F02 in Patients With Advanced Liver Fibrosis and/or With Mild Cirrhosiscompletedn=41
🐶 Hiring Signal
No open roles indexed yet — view Alentis Therapeutics AG jobs →

News

  • Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more
    New data for Genmab and AbbVie’s bispecific antibody Epkinly wowed analysts and could set the partners up for an expanded approval in diffuse large B cell lymphoma; deals have flowed steadily this…
    biospace · 1mo ago
  • Optogenetics researchers win a Nobel Prize; Roche bets on Alector brain drug
    The Nobel laureates “laid the foundation” for a new field of brain research, the award committee wrote. Elsewhere, Roche and CSL cut licensing deals and the FDA endorsed broader use of a Lilly medi…
    biopharma_dive · 1mo ago
  • CSL strikes up to $1.6B deal with Alentis for autoimmune drug with broad potential
    CSL will co-develop and co-promote Alentis Therapeutics' anti-claudin-1 therapy lixudebart for kidney and liver conditions, including primary sclerosing cholangitis and a systemic autoimmune diseas…
    biospace · 1mo ago
  • CSL pays $355M to co-develop Alentis’ phase 2-stage fibrosis drug
    Australia’s CSL is paying $355 million upfront for the rights to Alentis Therapeutics’ phase 2-stage fibrosis drug.
    fiercebiotech · 1mo ago
  • CSL to pay $355M upfront to co-develop Alentis’ kidney and liver drug
    The Australian drugmaker CSL will pay $355 million for Alentis Therapeutics’ anti-fibrosis drug, plus as much as $1.2 billion in future payments. Under the deal announced Sunday evening, CSL will c…
    endpoints · 1mo ago
identifiers
source
globaldata
top tags
Oncology1
mentioned in
5news items
entity-linker matched

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?